Developer docs
API playgroundTry for free, no card

Search company profiles

Sengenics

Full company profile

uuid000bfkf

Namestring
Sengenics
Websiteurl
sengenics.com
Company typeenum
Private
Founded yearint
1996
Descriptiontext

Sengenics is a Singapore-based functional proteomics company founded in 1996, operating with 51-100 employees as a privately held for-profit entity. The company's stated focus is leveraging its KREX™ protein folding technology for the identification of novel biomarkers, positioning it in the translational proteomics segment serving pharmaceutical, biotechnology, and academic research customers seeking high-fidelity antibody-based protein profiling.

The company's core asset is the KREX™ protein folding platform, described in source material as a technology that preserves correctly folded protein structures to enable biologically relevant antibody interactions, supporting applications in biomarker discovery, disease biology, drug screening, vaccine development, and the study of post-translational modifications. Leadership comprises CEO Jerry Williamson, Co-founder and Board Director Arif Anwar, and VP of Market and Business Development Fredrik Sundberg. A 2019 funding event tied to Cancer Research UK signals early institutional engagement in oncology-adjacent biomarker work.

The business model is not explicitly disclosed in the input data; no pricing structure, customer segments, revenue mechanics, or distribution channels are characterized. The firm appears to operate as a specialized tools and services provider in the functional proteomics niche, but the absence of revenue figures, named customers, product/service catalog, and go-to-market detail in the source material limits deeper characterization. It is worth noting that much of the detailed technology content in the source input pertains to SomaLogic's KREX™ platform rather than Sengenics' implementation, which constrains the specificity of this description.

Short descriptiontext

Sengenics is a Singapore-based functional proteomics company that uses its proprietary KREX™ protein folding technology to identify novel biomarkers, serving pharmaceutical, biotech, and academic translational research customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSingapore, Singapore
HQ citystring
Singapore
HQ countrystring
Singapore
HQ regionstring
Asia
Markets served

Serves global market

Keyword5 values
functional proteomics, biomarker discovery, antibody profiling, protein folding technology, immunoproteomics services
Industry1 code
PRIMARYHLAGADAG
Proteomics & Biomarker Analytical Testing
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Functional Proteomics
Social media profiles1 record
Cost components4 values
Personnel, Technology or R&D, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Sengenics is a functional proteomics company that leverages its proprietary KREX™ protein folding technology to enable high-plex antibody profiling and identification of novel biomarkers. The technology preserves correctly folded protein structures recognized by 90% of antibodies, supporting applications including biomarker discovery, disease biology research, drug screening, vaccine development, and post-translational modification studies for pharmaceutical, biotech, and academic research customers.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

No product information for Sengenics was found in the provided source data. The available sources contain information about SomaLogic's KREX™ Technology (antibody profiling platform) and industry news about the omics lab services market, but no direct references to Sengenics products, services, or technology offerings.

Product and service1 record
1KREX™ Technology Platform
CategoryFunctional Proteomics
Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Abcam (acquired by Danaher) is a major antibody and proteomics reagents provider serving academic and pharmaceutical researchers globally. Overlaps with Sengenics as a supplier of protein research tools used in biomarker discovery workflows.

TypeDirect peer
Description

Olink (acquired by Thermo Fisher Scientific in 2024) is the leading direct competitor in high-plex protein biomarker discovery using proximity extension assay (PEA) technology. Both Sengenics and Olink sell proteomics platforms to biopharma and academic researchers for biomarker discovery and translational applications.

TypeEmerging player
Description

Quanterix commercializes Simoa single-molecule array technology for ultra-sensitive protein detection. While focused more on low-plex ultra-sensitive assays, Quanterix overlaps with Sengenics in neurology and biomarker discovery research markets.

TypeDirect peer
Description

Standard BioTools provides mass cytometry and multiplexed protein profiling instruments used in translational research and biomarker discovery. Competes with Sengenics in proteomics research tools for pharma and academic customers.

TypeEmerging player
Description

IsoPlexis (now part of Bruker) provides single-cell proteomics platforms using antibody barcoding. Competes with Sengenics in functional proteomics and immune profiling applications for pharma and academic research.

TypeDirect peer
Description

Meso Scale Diagnostics (MSD) offers multiplexed immunoassay platforms for biomarker discovery and pharma research. MSD competes with Sengenics in high-multiplex antibody-based protein profiling for translational research applications.

TypeBroad incumbent
Description

Bio-Rad is a broad life science tools incumbent offering protein analysis instruments, Bio-Plex multiplex assay systems, and reagents. Overlaps with Sengenics in proteomics workflow tools sold to research and clinical research customers.

TypeEmerging player
Description

Seer offers the Proteograph platform for unbiased, deep proteomics using nanoparticle-based enrichment. Competes with Sengenics in biomarker discovery applications, particularly in large-scale population proteomics studies.

TypeBroad incumbent
Description

Cell Signaling Technology is a leading provider of antibodies and antibody-based proteomics reagents used in academic and pharma research. Overlaps with Sengenics in antibody-based protein detection workflows.

TypeDirect peer
Description

SomaLogic, acquired by Illumina, operates the SomaScan platform using SOMAmer/aptamer reagents to measure thousands of proteins simultaneously. Both companies compete in high-plex proteomics for biomarker discovery, with overlapping pharmaceutical and academic customer bases.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sengenics

Functional Proteomicssengenics.com

Sengenics is a Singapore-based functional proteomics company that uses its proprietary KREX™ protein folding technology to identify novel biomarkers, serving pharmaceutical, biotech, and academic translational research customers.

What Sengenics does

Sengenics is a Singapore-based functional proteomics company founded in 1996, operating with 51-100 employees as a privately held for-profit entity. The company's stated focus is leveraging its KREX™ protein folding technology for the identification of novel biomarkers, positioning it in the translational proteomics segment serving pharmaceutical, biotechnology, and academic research customers seeking high-fidelity antibody-based protein profiling.

The company's core asset is the KREX™ protein folding platform, described in source material as a technology that preserves correctly folded protein structures to enable biologically relevant antibody interactions, supporting applications in biomarker discovery, disease biology, drug screening, vaccine development, and the study of post-translational modifications. Leadership comprises CEO Jerry Williamson, Co-founder and Board Director Arif Anwar, and VP of Market and Business Development Fredrik Sundberg. A 2019 funding event tied to Cancer Research UK signals early institutional engagement in oncology-adjacent biomarker work.

The business model is not explicitly disclosed in the input data; no pricing structure, customer segments, revenue mechanics, or distribution channels are characterized. The firm appears to operate as a specialized tools and services provider in the functional proteomics niche, but the absence of revenue figures, named customers, product/service catalog, and go-to-market detail in the source material limits deeper characterization. It is worth noting that much of the detailed technology content in the source input pertains to SomaLogic's KREX™ platform rather than Sengenics' implementation, which constrains the specificity of this description.

Sengenics firmographics

Firmographics
Name
Sengenics
Website
https://sengenics.com
Company type
Private
Founded year
1996
Operating status
Operating
Headcount range
51–100 employees
Short description
Sengenics is a Singapore-based functional proteomics company that uses its proprietary KREX™ protein folding technology to identify novel biomarkers, serving pharmaceutical, biotech, and academic translational research customers.
Ownership category
akta.pro rank

Sengenics industry classification

Industry
Product category
Functional Proteomics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGADAG
Proteomics & Biomarker Analytical Testing

Keywords

  • Functional proteomics
  • Biomarker discovery
  • Antibody profiling
  • Protein folding technology
  • Immunoproteomics services

Where Sengenics is headquartered

Location

Headquarters

HQ city
Singapore
HQ country
Singapore
HQ region
Asia

Markets served

Sengenics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure

Sengenics product offering

Product offering

Core offering

Sengenics is a functional proteomics company that leverages its proprietary KREX™ protein folding technology to enable high-plex antibody profiling and identification of novel biomarkers. The technology preserves correctly folded protein structures recognized by 90% of antibodies, supporting applications including biomarker discovery, disease biology research, drug screening, vaccine development, and post-translational modification studies for pharmaceutical, biotech, and academic research customers.

Product overview

No product information for Sengenics was found in the provided source data. The available sources contain information about SomaLogic's KREX™ Technology (antibody profiling platform) and industry news about the omics lab services market, but no direct references to Sengenics products, services, or technology offerings.

Differentiator

Problem solved

Functional benefit

Products and services

  • KREX™ Technology Platform

Companies that use Sengenics

Customer profile

Ideal customer profiles2 records

Sengenics technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Sengenics partnerships and signals

Strategic signal

Recent moves4 records

Expansion highlights3 records

Sengenics competitors and assessment

Company assessment

Broad incumbents

  • Abcam: Abcam (acquired by Danaher) is a major antibody and proteomics reagents provider serving academic and pharmaceutical researchers globally. Overlaps with Sengenics as a supplier of protein research tools used in biomarker discovery workflows.
  • Bio-Rad Laboratories: Bio-Rad is a broad life science tools incumbent offering protein analysis instruments, Bio-Plex multiplex assay systems, and reagents. Overlaps with Sengenics in proteomics workflow tools sold to research and clinical research customers.
  • Cell Signaling Technology: Cell Signaling Technology is a leading provider of antibodies and antibody-based proteomics reagents used in academic and pharma research. Overlaps with Sengenics in antibody-based protein detection workflows.

Direct peers

  • Olink Holding: Olink (acquired by Thermo Fisher Scientific in 2024) is the leading direct competitor in high-plex protein biomarker discovery using proximity extension assay (PEA) technology. Both Sengenics and Olink sell proteomics platforms to biopharma and academic researchers for biomarker discovery and translational applications.
  • Standard BioTools (formerly Fluidigm): Standard BioTools provides mass cytometry and multiplexed protein profiling instruments used in translational research and biomarker discovery. Competes with Sengenics in proteomics research tools for pharma and academic customers.
  • Meso Scale Diagnostics: Meso Scale Diagnostics (MSD) offers multiplexed immunoassay platforms for biomarker discovery and pharma research. MSD competes with Sengenics in high-multiplex antibody-based protein profiling for translational research applications.
  • SomaLogic (now Illumina): SomaLogic, acquired by Illumina, operates the SomaScan platform using SOMAmer/aptamer reagents to measure thousands of proteins simultaneously. Both companies compete in high-plex proteomics for biomarker discovery, with overlapping pharmaceutical and academic customer bases.

Emerging players

  • Quanterix: Quanterix commercializes Simoa single-molecule array technology for ultra-sensitive protein detection. While focused more on low-plex ultra-sensitive assays, Quanterix overlaps with Sengenics in neurology and biomarker discovery research markets.
  • IsoPlexis: IsoPlexis (now part of Bruker) provides single-cell proteomics platforms using antibody barcoding. Competes with Sengenics in functional proteomics and immune profiling applications for pharma and academic research.
  • Seer: Seer offers the Proteograph platform for unbiased, deep proteomics using nanoparticle-based enrichment. Competes with Sengenics in biomarker discovery applications, particularly in large-scale population proteomics studies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Sengenics social profiles

Digital presence

Sengenics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sengenics leadership team

Management profile

Number of profiles

Profiles3 records

Sengenics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sengenics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sengenics

What does Sengenics do?

Sengenics is a functional proteomics company that leverages its proprietary KREX™ protein folding technology to enable high-plex antibody profiling and identification of novel biomarkers. The technology preserves correctly folded protein structures recognized by 90% of antibodies, supporting applications including biomarker discovery, disease biology research, drug screening, vaccine development, and post-translational modification studies for pharmaceutical, biotech, and academic research customers.

Is Sengenics a public or private company?

Sengenics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Sengenics founded?

Sengenics was founded in 1996. It employs 51 to 100 people.

Where is Sengenics based?

Sengenics is headquartered in Singapore, Singapore, in the Asia region.

Who are Sengenics's main competitors?

Broad incumbents on record are Abcam, Bio-Rad Laboratories and Cell Signaling Technology. Direct peers are Olink Holding, Standard BioTools (formerly Fluidigm), Meso Scale Diagnostics and SomaLogic (now Illumina). Emerging players are Quanterix, IsoPlexis and Seer.

Does Sengenics have an API?

No public API is recorded for Sengenics.

What industry is Sengenics in?

Sengenics's product category is Functional Proteomics. Its primary akta.pro industry code is HLAGADAG, Proteomics & Biomarker Analytical Testing. Its NAICS code is 541714 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireSengenics Corporation dévoile i-Ome® Cancer : Une avancée dans la médecine de précision du cancerSengenics Corporation LLC announced the launch of i-Ome Cancer, a high-throughput immunoproteomics platform for cancer biomarker discovery using a simple blood sample. The platform utilizes the company's proprietary KREX® technology and includes a targeted library of over 500 proteins, enabling screening of twice as many auto-antibodies as its predecessor. The tool is now available through service providers worldwide to advance precision oncology research.PR NewswireSengenics Corporation stellt i-Ome® Cancer vor: Ein Durchbruch in der KrebspräzisionsmedizinSengenics Corporation announced the launch of i-Ome Cancer, a high-throughput immunoproteomics platform for cancer biomarker discovery using a single drop of blood. The platform utilizes the company's proprietary KREX® technology and features a curated library of over 500 cancer-associated proteins, enabling double the autoantibody screening capacity of its predecessor. The tool is now available worldwide through service providers for research purposes only.PR NewswireSengenics Corporation Unveils i-Ome® Cancer: A Breakthrough in Cancer Precision MedicineSengenics Corporation announced the launch of i-Ome Cancer, a high-throughput immunoproteomic research tool designed to discover cancer biomarkers through autoantibody profiling from a blood sample. The platform utilizes the company's proprietary KREX® technology and features a curated library of over 500 autoantigenic proteins, enabling screening at twice the capacity of its predecessor. i-Ome Cancer is now available globally through service providers for research purposes, supporting earlier cancer diagnoses and the development of cancer vaccines and therapies.PR NewswireSengenics Corporation presenta i-Ome® Cancer: un gran avance en la medicina de precisión contra el cáncerSengenics Corporation LLC announced the launch of i-Ome Cancer, a high-throughput immunoproteomics platform for cancer biomarker discovery that requires only a drop of blood. The platform leverages the company's proprietary KREX® technology and includes a curated library of over 500 autoantigenic proteins associated with cancer, analyzing twice as many autoantibodies as its predecessor. The tool is now available globally through service providers to advance early cancer diagnostics, therapeutic vaccine development, and precision cancer medicine.PR NewswireSengenics Corporation Announces New Collaboration to Advance Cancer TreatmentSengenics Corporation and Duke Health announced a collaboration to investigate the immune system's response to immunotherapy for metastatic colorectal cancer using Sengenics's KREX® technology. The partnership aims to identify autoantibody biomarkers that can help stratify patients and improve treatment efficacy, resistance management, and toxicity monitoring. This initiative seeks to redefine mCRC treatment by leveraging precision medicine insights into the humoral immune response.PR NewswireSengenics Corporation Announces Key Distributor in ChinaSengenics Corporation LLC has entered into a sales distribution and services agreement with Shanghai Universal Biotech Co., Ltd. (UniV) to expand the reach of Sengenics' KREX® immunoprofiling technology in China. The partnership will serve pharmaceutical, biotech, and academic institutions throughout China with autoantibody biomarker discovery capabilities. Sengenics, headquartered in Boston, Massachusetts, will leverage UniV's network of 26 offices and 10 sales subsidiaries across China to broaden its market presence in Asia.BioSpaceSengenics Broadens Its Systems Serology Tools to Enable the Detection of a Wider Range of Autoantibody BiomarkersSengenics announced the commercial launch of Dual-Color IgG/IgA Assay Services, enabling simultaneous detection of IgG and IgA autoantibodies from low sample volumes. The assays run on all Sengenics protein arrays and expand biomarker discovery across autoimmune, immuno-oncology, and neuroinflammation fields.BioSpaceSengenics Prepares for Next Phase Growth and Welcomes Bioscience Industry Leader as New CEOSengenics appointed Jerry Williamson as CEO, effective immediately, replacing Arif Anwar. Williamson brings over 30 years of bioscience experience, and Summa Equity holds a majority stake. Anwar will remain on the board in an advisory role.PrwebSengenics Ramps Up for Further Growth, Announces Expansion of its Sales and Business Development Teams in the USA, Europe and AsiaSengenics announced expansion of its global sales and business development teams in the USA, Europe, and Asia. The company is collaborating with 8 of the world's top pharmaceutical companies on its KREX technology. It plans to expand applications in companion diagnostics for cancer and autoimmune drugs.